RxSight, Inc.
RXST
$12.62
-$0.47-3.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -14.09% | -3.58% | 28.41% | 40.71% | 59.08% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.09% | -3.58% | 28.41% | 40.71% | 59.08% |
| Cost of Revenue | -39.44% | -20.59% | 8.37% | 4.58% | 19.20% |
| Gross Profit | -3.94% | 3.88% | 36.95% | 63.07% | 83.67% |
| SG&A Expenses | 6.78% | 19.28% | 22.77% | 33.19% | 33.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.54% | 10.23% | 20.87% | 23.86% | 28.32% |
| Operating Income | -32.00% | -68.04% | -0.04% | 20.49% | 26.26% |
| Income Before Tax | -55.04% | -93.86% | 10.11% | 35.55% | 49.00% |
| Income Tax Expenses | -23.08% | 100.00% | 100.00% | 166.67% | 8.33% |
| Earnings from Continuing Operations | -54.88% | -93.88% | 10.00% | 35.29% | 48.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.88% | -93.88% | 10.00% | 35.29% | 48.95% |
| EBIT | -32.00% | -68.04% | -0.04% | 20.49% | 26.26% |
| EBITDA | -39.92% | -75.75% | -3.59% | 17.22% | 29.19% |
| EPS Basic | -50.41% | -82.99% | 18.14% | 42.36% | 54.24% |
| Normalized Basic EPS | -50.50% | -83.05% | 18.22% | 42.55% | 48.42% |
| EPS Diluted | -50.41% | -82.99% | 18.14% | 42.36% | 54.24% |
| Normalized Diluted EPS | -50.50% | -83.05% | 18.22% | 42.55% | 48.42% |
| Average Basic Shares Outstanding | 2.96% | 5.95% | 9.95% | 12.22% | 11.57% |
| Average Diluted Shares Outstanding | 2.96% | 5.95% | 9.95% | 12.22% | 11.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |